Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Ascendis Pharma ( (ASND) ).
On April 6, 2026, Ascendis Pharma announced that the U.S. Food and Drug Administration granted orphan drug exclusivity to YUVIWEL (navepegritide), developed as TransCon CNP, and that the therapy is now commercially available in the United States. YUVIWEL is the first and only once-weekly treatment approved in the U.S. to increase linear growth in children aged two and older with achondroplasia and open epiphyses, providing continuous systemic exposure to CNP and securing market exclusivity through February 27, 2033, which strengthens Ascendis Pharma’s position in the rare disease growth-disorders segment and could underpin a durable revenue stream in this niche market.
The most recent analyst rating on (ASND) stock is a Buy with a $342.00 price target. To see the full list of analyst forecasts on Ascendis Pharma stock, see the ASND Stock Forecast page.
Spark’s Take on ASND Stock
According to Spark, TipRanks’ AI Analyst, ASND is a Neutral.
The score is driven primarily by improving fundamentals (rapid revenue growth, strong margins, and a move to positive operating/free cash flow) but is held back by balance-sheet risk (negative equity and high debt) and unprofitable earnings (negative P/E). Technicals are neutral-to-slightly cautious, while the latest earnings call adds support via upbeat guidance and commercial/pipeline momentum despite elevated operating expenses and near-term volatility risks.
To see Spark’s full report on ASND stock, click here.
More about Ascendis Pharma
Ascendis Pharma A/S is a Denmark-based biopharmaceutical company focused on developing and commercializing therapies using its TransCon technology platform. The company targets serious unmet medical needs, including rare endocrine and growth disorders, with long-acting treatments designed to improve convenience and clinical outcomes for patients.
Average Trading Volume: 684,318
Technical Sentiment Signal: Buy
Current Market Cap: $14.07B
See more insights into ASND stock on TipRanks’ Stock Analysis page.